Medical and Recreational Marijuana Shows No Proven Benefit for Mental Health, New Analyses Find
Two recent analyses of gold‑standard research conclude that using cannabis—whether for medical or recreational purposes—does not effectively treat common mental health conditions such as anxiety, depression, or post‑traumatic stress disorder.
Medical marijuana products typically contain cannabidiol (CBD) and delta‑9‑tetrahydrocannabinol (THC), the compound responsible for the plant’s euphoric effects.
Jack Wilson, a postdoctoral research fellow at the University of Sydney’s Matilda Centre for Research in Mental Health and Substance Use, led one of the studies published in The Lancet Psychiatry. He explained, “We found no evidence any form of cannabis is effective in treating anxiety, depression or post‑traumatic stress disorder, which are three of the leading reasons for which cannabis is prescribed.”
The Lancet review examined 54 randomized controlled trials conducted between 1980 and 2025. Wilson noted that the cannabis medications used in those trials were mainly oral formulations—capsules, sprays, or oils—while real‑world users often smoke the plant, for which there is even less evidence of benefit.
According to Wilson, marijuana also failed to improve other mental health issues, including anorexia nervosa, bipolar disorder, obsessive‑compulsive disorder (OCD), and psychotic disorders such as schizophrenia.
Experts acknowledge that marijuana studies are frequently small and challenging to conduct, but the randomized controlled trials included in the Lancet analysis represent the highest standard of evidence. Dr. Deepak Cyril D’Souza, Vikram Sodhi ’92 Professor of Psychiatry and director of the Yale Center for the Science of Cannabis and Cannabinoids, emphasized that these trials are “the gold‑standard of research.”
D’Souza, who was not involved in the Lancet study, is the senior author of a recent JAMA paper that similarly evaluated natural and synthetic CBD and THC for mental health conditions. He stated, “These two papers clearly show there isn’t any evidence to recommend the use of cannabis or cannabis derivatives to treat mental health. Yet almost every state in the US approves medical marijuana for mental health conditions.”
Growing Use Despite Lack of Proof
While evidence of benefit remains scarce, the use of medical and recreational marijuana for mental health continues to rise. Wilson reported that roughly 27 % of people aged 16 to 65 in the United States and Canada have used marijuana for medical purposes, with about half citing mental‑health management as their primary motive.
He added, “Despite a lack of proof of efficacy, doctors continue to prescribe medical marijuana to treat mental health conditions,” noting that the cannabis industry’s ties to some research studies create potential conflicts of interest that could influence findings.
Potential Hazards, Especially for Vulnerable Groups
Regular use of high‑potency marijuana poses risks, particularly for pregnant individuals, adolescents, and young adults. Consumption during these developmental periods can interfere with brain maturation.
Among teens and young adults with mood disorders—such as depression or bipolar disorder—heavy marijuana use is associated with an increased likelihood of self‑harm, suicide attempts, and death.
For those with a family history of bipolar or psychotic disorders, marijuana use can raise the chance of developing a psychotic or mental health condition. After a mental health diagnosis, continued use may worsen cognition and increase the risk of relapse.
D’Souza warned, “While there may be thousands, perhaps millions, of people who use cannabis sporadically, in very modest amounts and do not experience adverse events, we also know of people who used cannabis a few times and suffered catastrophic adverse events that altered the trajectory of their life forever.”
He further noted that daily users of high‑potency cannabis may be six times more likely to develop a psychotic disorder such as schizophrenia or bipolar disorder compared with individuals who have never used cannabis.
Today’s Weed Is More Powerful and Addictive
The potency of modern cannabis has surged dramatically. D’Souza pointed out that THC levels have risen from roughly 4 % in the 1970s to an average of 18 % to 20 % today.
“You can now buy cannabis in dispensaries that has a THC content of 35 %,” he said. “Marijuana concentrates, which are analogous to nicotine concentrates, can reach THC levels of 80 %. That’s about 20 times greater than the THC content of cannabis from the 1960s and ‘70s.”
This increase in strength correlates with a rise in addiction. In the United States, approximately three in ten people who use marijuana meet the criteria for cannabis use disorder, the clinical term for marijuana addiction, according to the US Centers for Disease Control and Prevention.
Cannabis use disorder—also called marijuana use disorder—is marked by dependence, which may manifest as food cravings, reduced appetite, irritability, restlessness, and mood or sleep difficulties after cessation, as outlined by the National Institute on Drug Abuse.
Effective Alternatives for Mental Health Care
Evidence‑based treatments remain available for anxiety, depression, and related conditions. Selective serotonin reuptake inhibitors (SSRIs) are a common pharmaceutical approach for depression and anxiety.
The leading psychotherapy for these disorders is cognitive behavioral therapy (CBT), which is often combined with SSRIs. CBT is goal‑oriented, focusing on altering negative thoughts and behaviors to improve emotional regulation and mood.
Resources for locating qualified CBT therapists include the Association for Behavioral and Cognitive Therapies’ searchable directory by zip code and the American Psychological Association’s “Find a Psychologist” tool, which lists CBT‑trained clinicians under treatment methods.
For more information on maintaining well‑being, consider signing up for CNN’s Life, But Better newsletter.
Source: Here
